Moberg Pharma AB (Publ) Year-end Report 2014
SUCCESSFUL FOURTH QUARTER AND THE FIRST PROFITABLE FULL YEARPERIOD (JAN-DEC 2014) · Revenue MSEK 200.2 (157.4) · EBITDA MSEK 25.3 (loss: 7.9) · EBITDA for existing product portfolio MSEK 43.4 (17.4) · Operating profit (EBIT) MSEK 17.2 (loss: 14.1) · Net profit after tax MSEK 12.3 (loss: 11.4) · Earnings per share SEK 0.95 (loss: 1.01) · Operating cash flow per share SEK 1.27 (neg: 0.27) · The Board proposes that no dividend will be distributed for the 2014 financial year FOURTH QUARTER (OCT-DEC 2014) · Revenue MSEK 44.5 (36.8) · EBITDA MSEK 3.6 (2.4) ·